Skip to content

Galantamine

Also called Razadyne — a competitive reversible acetylcholinesterase inhibitor

A tertiary alkaloid and a competitive, reversible inhibitor of acetylcholinesterase.

  • TypeSmall molecule
  • FormOral
  • Researched forCognitive & Mood

Where to get Galantamine

RUPharma
Oral
Code CAMERON

Sold as the form named. Approved uses are on its label; the research here goes beyond them.

Shop oral at RUPharma
Before you run this, know your numbers

Approved for mild-to-moderate Alzheimer's dementia, and also sold as a supplement-adjacent nootropic, which is how most people meet it.

Its label reports two two-year randomized trials in MILD COGNITIVE IMPAIRMENT — not dementia — in which 13 patients on the drug died against 1 on placebo, about half from vascular causes, and that finding has never been explained. Mild cognitive impairment is the population closest to somebody buying this for a memory that feels slower, so knowing your own vascular numbers is not optional here.

Order these through my Marek link

The short version

  • Why people research itFocus, memory, neuroprotection, mood and stress resilience.
  • What the evidence isThe label's mild cognitive impairment paragraph comes first.
  • What to watchA very slow pulse or fainting.

How Galantamine works

A tertiary alkaloid and a competitive, reversible inhibitor of acetylcholinesterase; the label states the precise mechanism is unknown and that the effect is postulated to come from enhanced cholinergic function. The claim this molecule is best known for outside medicine — allosteric potentiation of nicotinic acetylcholine receptors — does not appear in the approved mechanism statement, and is a pharmacology-literature claim rather than a label one. Roughly 90% orally bioavailable, only 18% protein bound, cleared by CYP2D6, CYP3A4 and the kidney.

Read the label's mild cognitive impairment paragraph before anything else on this page. In two randomized placebo-controlled trials of two years' duration in people with mild cognitive impairment, 13 patients on galantamine (n=1026) and 1 patient on placebo (n=1022) died Galantamine label 2021.

That paragraph is a finding, not a warning label boilerplate, and it deserves a fair reading. Thirteen against one is a small absolute number in a two-year study of two thousand elderly people, the causes were mixed, and the label itself frames them as causes expected in an elderly population. It was still enough of a signal for a regulator to require it in the label of a drug approved for a different, sicker population.

  • Oral

On the goal map: Cholinergic — attention, encoding & recall (Focus, memory & cognition)

Research on Galantamine6 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Approved for mild to moderate Alzheimer's dementia. Its label reports two 2-year randomized trials in mild cognitive impairment with 13 deaths on drug against 1 on placebo.

Human clinical evidence

  • The label's mild cognitive impairment paragraph comes first. In two randomized placebo-controlled trials of two years' duration in MCI, 13 patients on galantamine (n=1026) and 1 on placebo (n=1022) died — 10.2 against 0.7 per 1000 person-years, about half from vascular causes. Mild cognitive impairment is not dementia; it is the closest studied population to somebody whose memory feels a step slower.

  • Approved for mild to moderate Alzheimer's dementia. Two large syntheses read it differently: the 80-trial individual-patient analysis lists it among the single agents that did NOT clear a 1.40-MMSE-point threshold (Veroniki 2022), while the 2026 network of 125 trials ranks it highest of any drug at 0.40 (Li 2026). Same drug, two defensible methods.

Correlative data

  • The disagreement above is methodological: absolute MMSE points against standardized effect sizes. Both papers report wide intervals, and Veroniki 2022 states that two-thirds of its included trials were at high risk of bias for incomplete outcome data.

  • The unofficial non-medical use — is supported by the drug's ~1 hour peak and ~7 hour half-life and studied by nobody. There is no published cardiovascular or sleep-architecture data for that pattern.

How the mechanism reads

  • A tertiary alkaloid and competitive, reversible acetylcholinesterase inhibitor. The nicotinic allosteric potentiation claim this molecule is famous for outside medicine does not appear in the approved mechanism statement — it is a pharmacology-literature claim quoted as a label one.

    Mechanistic
  • Predicted downside, from the label: bradycardia, syncope and heart block; exaggerated neuromuscular blockade under anesthesia, which anyone taking it must disclose before surgery; caution in severe asthma and COPD; and monitoring for gastrointestinal bleeding.

    Mechanistic

Sources

  • U.S. Food and Drug Administration. Galantamine tablets - full prescribing information, including the mild cognitive impairment mortality paragraph, the competitive reversible acetylcholinesterase inhibition statement and the CYP2D6 and CYP3A4 metabolism section. DailyMed, U.S. National Library of Medicine; Aurobindo Pharma Limited label version 14, revised August 2021
  • Li Y, Li L, Yang Q, Xiong J. Comparative Efficacy and Safety of Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Current Alzheimer Research 2026 · PMID 42099163
  • Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open 2022 · PMID 35473731
  • Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews 2021 · PMID 35608903
  • Kim Y, Kang DW, Kim GH, et al. (Korean Dementia Association). Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders 2025 · PMID 39944527

Galantamine safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Mild cognitive impairment, because two trials showed more deaths on drug than on placebo.
  • Slow heart rate, heart block or unexplained fainting.
  • Severe liver or kidney impairment.
  • Asthma or COPD.
  • Stomach ulcers or gastrointestinal bleeding.

What’s expected

  • Nausea, vomiting and diarrhea early on.
  • Vivid dreams, insomnia and weight loss.
  • Cholinergic effects that also come from nicotinic modulation.

Watch for

  • A very slow pulse or fainting.
  • Black tarry stools, as cholinergic drive raises gastric acid and ulcer risk.
  • Marked weight loss.

Labs that tell you it’s working

  • Comprehensive Metabolic Panel: liver enzymes, as it is cleared hepatically and renally.
  • Cystatin C with eGFR: renal clearance sets exposure.

Competitive reversible acetylcholinesterase inhibitor with nicotinic allosteric modulation; an excess-death signal appeared in mild cognitive impairment trials. PMID 42099163 PMID 35608903

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

Galantamine FAQ4 common questions

Is Galantamine approved for human use?
Galantamine is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
What is Galantamine researched for?
Focus, memory, neuroprotection, mood and stress resilience.
Which labs show whether it's doing anything?
Comprehensive Metabolic Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Galantamine: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Galantamine is. Skool covers how it is run.

Free on this page

What Galantamine is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Galantamine is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool